• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Scopus
  4. Citraconate inhibits ACOD1 (IRG1) catalysis, reduces interferon responses and oxidative stress, and modulates inflammation and cell metabolism
 
  • Details
  • Full
Options
2022
Journal Article
Title

Citraconate inhibits ACOD1 (IRG1) catalysis, reduces interferon responses and oxidative stress, and modulates inflammation and cell metabolism

Abstract
Although the immunomodulatory and cytoprotective properties of itaconate have been studied extensively, it is not known whether its naturally occurring isomers mesaconate and citraconate have similar properties. Here, we show that itaconate is partially converted to mesaconate intracellularly and that mesaconate accumulation in macrophage activation depends on prior itaconate synthesis. When added to human cells in supraphysiological concentrations, all three isomers reduce lactate levels, whereas itaconate is the strongest succinate dehydrogenase (SDH) inhibitor. In cells infected with influenza A virus (IAV), all three isomers profoundly alter amino acid metabolism, modulate cytokine/chemokine release and reduce interferon signalling, oxidative stress and the release of viral particles. Of the three isomers, citraconate is the strongest electrophile and nuclear factor-erythroid 2-related factor 2 (NRF2) agonist. Only citraconate inhibits catalysis of itaconate by cis-aconitate decarboxylase (ACOD1), probably by competitive binding to the substrate-binding site. These results reveal mesaconate and citraconate as immunomodulatory, anti-oxidative and antiviral compounds, and citraconate as the first naturally occurring ACOD1 inhibitor.
Author(s)
Chen, F.
Helmholtz Centre for Infection Research (HZI)
Elgaher, W.A.M.
Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)
Winterhoff, M.
Helmholtz Centre for Infection Research (HZI)
Büssow, K.
Helmholtz Centre for Infection Research (HZI)
Waqas, F.H.
Helmholtz Centre for Infection Research (HZI)
Graner, E.
Helmholtz Centre for Infection Research (HZI)
Pires-Afonso, Y.
Luxembourg Institute of Health
Casares Perez, L.
University of Dundee
Vega, L. de la
University of Dundee
Sahini, N.
Helmholtz Centre for Infection Research (HZI)
Czichon, L.
Helmholtz Centre for Infection Research (HZI)
Zobl, Walter
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM  
Zillinger, T.
Universitätsklinikum Bonn
Shehata, M.
Universität Gießen Fachbereich Medizin
Pleschka, S.
Universität Gießen Fachbereich Medizin
Bähre, H.
Medizinische Hochschule Hannover (MHH)
Falk, C.
Medizinische Hochschule Hannover (MHH)
Michelucci, A.
Luxembourg Institute of Health
Schuchardt, Sven  
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM  
Blankenfeldt, W.
Helmholtz Centre for Infection Research (HZI)
Hirsch, A.K.H.
Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)
Pessler, F.
Helmholtz Centre for Infection Research (HZI)
Journal
Nature metabolism  
Open Access
DOI
10.1038/s42255-022-00577-x
Language
English
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024